Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed amning

Janusmed amning – vedolizumab

Janusmed amning tillhandahåller generella rekommendationer om huruvida ett friskt fullgånget spädbarn kan ammas när modern använder olika läkemedel. Observera att prematura och/eller sjuka spädbarn alltid kräver särskilda överväganden. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed amning och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Vedolizumab Testmiljö

Vedolizumab

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Julsgaard M, Kjeldsen J, Bibby BM, Brock B, Baumgart DC. Vedolizumab Concentrations in the Breast Milk of Nursing Mothers With Inflammatory Bowel Disease. Gastroenterology. 2018;154(3):752-754e1.

  2. Lahat A, Shitrit AB, Naftali T, Milgrom Y, Elyakim R, Goldin E et al. Vedolizumab Levels in Breast Milk of Nursing Mothers With Inflammatory Bowel Disease. J Crohns Colitis. 2018;12:120-123.

  3. Sun W, Fennimore B, Beaulieu DB, Arsenescu R, Stein AC, Chen J et al. Vedolizumab Concentrations in Breast Milk: Results from a Prospective, Postmarketing, Milk-Only Lactation Study in Nursing Mothers with Inflammatory Bowel Disease. Clin Pharmacokinet. 2021;60(6):811-818.

  4. Julsgaard M, Baumgart DC, Baunwall SMD, Hansen MM, Grosen A, Bibby BM et al. Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population-based cohort study. Aliment Pharmacol Ther. 2021;54(10):1320-1329.

  5. Moens A, van Hoeve K, Humblet E, Rahier JF, Bossuyt P, Dewit S et al. Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab. J Crohns Colitis. 2019;13(1):12-18.

  6. Pinto FPJ, Dutra RM, Almeida LC, Craveiro MMS, Baima JP, Saad-Hossne R et al. Vedolizumab Safety During Pregnancy and Lactation in a Patient with Ulcerative Colitis: A Case Report. Clin Exp Gastroenterol. 2024;17:165-171.

  7. Mitrova K, Pipek B, Bortlik M, Bouchner L, Brezina J, Douda T et al. Safety of Ustekinumab and Vedolizumab During Pregnancy-Pregnancy, Neonatal, and Infant Outcome: A Prospective Multicentre Study. J Crohns Colitis. 2022;16(12):1808-1815.

  1. Julsgaard M, Kjeldsen J, Bibby BM, Brock B, Baumgart DC. Vedolizumab Concentrations in the Breast Milk of Nursing Mothers With Inflammatory Bowel Disease. Gastroenterology. 2018;154(3):752-754e1.
  2. Lahat A, Shitrit AB, Naftali T, Milgrom Y, Elyakim R, Goldin E et al. Vedolizumab Levels in Breast Milk of Nursing Mothers With Inflammatory Bowel Disease. J Crohns Colitis. 2018;12:120-123.
  3. Sun W, Fennimore B, Beaulieu DB, Arsenescu R, Stein AC, Chen J et al. Vedolizumab Concentrations in Breast Milk: Results from a Prospective, Postmarketing, Milk-Only Lactation Study in Nursing Mothers with Inflammatory Bowel Disease. Clin Pharmacokinet. 2021;60(6):811-818.
  4. Julsgaard M, Baumgart DC, Baunwall SMD, Hansen MM, Grosen A, Bibby BM et al. Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population-based cohort study. Aliment Pharmacol Ther. 2021;54(10):1320-1329.
  5. Moens A, van Hoeve K, Humblet E, Rahier JF, Bossuyt P, Dewit S et al. Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab. J Crohns Colitis. 2019;13(1):12-18.
  6. Pinto FPJ, Dutra RM, Almeida LC, Craveiro MMS, Baima JP, Saad-Hossne R et al. Vedolizumab Safety During Pregnancy and Lactation in a Patient with Ulcerative Colitis: A Case Report. Clin Exp Gastroenterol. 2024;17:165-171.
  7. Mitrova K, Pipek B, Bortlik M, Bouchner L, Brezina J, Douda T et al. Safety of Ustekinumab and Vedolizumab During Pregnancy-Pregnancy, Neonatal, and Infant Outcome: A Prospective Multicentre Study. J Crohns Colitis. 2022;16(12):1808-1815.

Innehållet senast uppdaterat 11/7/2024